# Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma

> **NCT07468630** · PHASE2 · RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 106 (estimated)

## Conditions studied

- Colon Adenocarcinoma

## Interventions

- **DRUG:** Tolecizumab (PCSK9 Inhibitor)
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT07468630
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468630, "Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07468630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*